CytomX Therapeutics Inc (NAS:CTMX)
$ 1.02 0 (0%) Market Cap: 79.82 Mil Enterprise Value: -27.17 Mil PE Ratio: 6.00 PB Ratio: 0 GF Score: 52/100

CytomX Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 03:00PM GMT
Release Date Price: $1.65 (-4.07%)
Mitchell Kapoor
H.C. Wainwright & Co., LLC - Analyst

Hey, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst here at H.C. Wainwright. It's my pleasure to welcome you to the BioConnect Conference.

Joining me today is Sean McCarthy, CEO of CytomX. It's an exciting time for CytomX, and I'm glad that he could join me. So maybe, Sean, if you could give us an overview of the CytomX pipeline, what you're doing today, and just how you're differentiated.

Sean McCarthy
CytomX Therapeutics, Inc. - CEO and Chairman

Yeah. Thanks, Mitch. Thanks for the invitation. Pleasure to be here. So CytomX Therapeutics is focused on a concept that when we look at the current evolution of biologic therapies in oncology, there's an increasing move to more and more potent formats: so immunotherapies, antibody drug conjugates, bispecifics, and cytokines as examples. And what we've observed, I think, as a field, is that as we've tried to drive the potency of these agents, it can be difficult to separate the potency from the toxicity.

So our thesis at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot